Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant risks » significant risk (Expand Search), significant results (Expand Search), significant role (Expand Search)
risks decrease » sizes decrease (Expand Search), visits decreased (Expand Search), rivers decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant risks » significant risk (Expand Search), significant results (Expand Search), significant role (Expand Search)
risks decrease » sizes decrease (Expand Search), visits decreased (Expand Search), rivers decreased (Expand Search)
-
2821
-
2822
-
2823
Egg-induced IL-1β and IL-17 production is dependent on both Caspase-1 and Caspase-8.
Published 2025Subjects: -
2824
-
2825
RNA targets and biological process GO terms associated with Mod RiP-Seq analysis.
Published 2024Subjects: -
2826
Comparison of postoperative rest and activity between APS score groups in Experiment 2.
Published 2025Subjects: -
2827
Phylogenetic analysis of <i>Anaplasma</i> spp. based on the partial 16S rRNA gene sequence.
Published 2025Subjects: -
2828
-
2829
Downregulation of miR-1247-3p inhibited apoptosis and reduced chemosensitivity in cells.
Published 2024Subjects: -
2830
Negative (Prednisone) and basal (ATP) control compounds binding to ALK protein.
Published 2025Subjects: -
2831
-
2832
-
2833
-
2834
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
2835
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
2836
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
2837
Raw data.
Published 2025“…Restricted cubic spline analysis further demonstrated that the risk of vertebral fractures decreased as the RC level and the RC-to-cholesterol ratio increased. …”
-
2838
Baseline characteristics of the subjects.
Published 2025“…Restricted cubic spline analysis further demonstrated that the risk of vertebral fractures decreased as the RC level and the RC-to-cholesterol ratio increased. …”
-
2839
-
2840